Novartis International AG /
Novartis presents new data from large European study reinforcing the benefit of
first-line Tasigna® in newly-diagnosed patients with CML
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announce ...
↧